Latest News
Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline
Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix's AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.
e-ASPECTS Demonstrates 100% Sensitivity to Intracranial Hemorrhage (ICH) in New Study
Study conducted at UCL Hospital in London adds to the growing body of real-world evidence showcasing the clinical value that e-ASPECTS can deliver to stroke teams.
New e-Lung Study with AstraZeneca Published in ATS Journal
Study demonstrates the value of our unique e-Lung biomarkers to accurately predict IPF patients at risk of future lung function decline, a prognostic capability which can benefit future clinical trials.
New Study: Brainomix 360 Stroke Delivers Improved Patient Outcomes
A newly published study in Frontiers demonstrates the impact of the Brainomix 360 Stroke platform, trebling the number of stroke patients achieving a better outcome.
New Study Strengthens the Value of e-ASPECTS and Simple Imaging in Stroke Treatment Decision Making
Results will enable stroke networks to make more confident treatment decisions in both specialist and non-specialist stroke hospitals
New Results: Brainomix Software Shown to Improve Stroke Treatment Rates at Budapest University Hospital
e-Stroke Suite increased thrombolysis and thrombectomy treatment rates for stroke patients
New Study: Using Simple Brain Scans Brainomix AI Software Can Generate Critical Information for the Treatment of Stroke Patients
New study shows Brainomix’s unique AI-driven software gives doctors reliable information to treat stroke patients from universally available imaging systems
Brainomix Software Used to Select Patients in Ground-Breaking Brazilian Stroke Trial
First trial to demonstrate efficacy of thrombectomy in developing world healthcare system
New Study: Brainomix Stroke Imaging Solution Improves Consistency of Image Interpretation for Doctors
New study shows Brainomix e-CTA provides similar measures to experts and improves inter-rater reliability
New ESO Guidelines on Mechanical Thrombectomy
Guidelines reinforce the importance of imaging in determining patient eligibility
New Study Highlights Clinical Value of Brainomix's e-ASPECTS Software for Stroke Patients
Ischemic injury on e-ASPECTS, but not RAPID software, predicted good clinical outcome at 3 months after stroke
Study Shows e-ASPECTS May Be Sufficient for Selection of Late-Time Window Thrombectomy Patients
Study suggests it may be reasonable to select patients for thrombectomy in centres without access to advanced imaging using the e-ASPECTS tool in combination with clinical criteria
New Study: e-ASPECTS Predicts Patient Outcome and Risk of Bleeding in Acute Stroke
New publication in Stroke journal with 1,500 patients from the ENCHANTED trial database
e-ASPECTS in Thrombectomy Trial in Brazil
The only mechanical thrombectomy trial in a developing country is currently taking place in Brazil
American Journal of Neuroradiology Publication
A new study shows e-ASPECTS correlates with and is a predictor of outcome
International Journal of Stroke Publication
Results show e-ASPECTS is on average statistically non-inferior to expert neuroradiologists
Journal of Cerebrovascular Diseases Publication
Study illustrates the potential benefits of e-ASPECTS when integrated within Mobile Stroke Units
International Journal of Stroke Publication
Study shows e-ASPECTS performs as well as stroke experts when assessing brain CT scans of stroke patients
Our Partners
